Arrhythmias & electrophysiologyCase-control study
Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation
- Case-control study
- prospective
- single-centre
- sex-, age- and ethnicity-matched healthy controls
Authors' conclusion
Patients with SCVF harbor circulating autoantibodies against the cardiac TREK-1 channel.
Study context
- Population
- Cardiac arrest survivors diagnosed with short-coupled ventricular fibrillation (SCVF) or idiopathic ventricular fibrillation (IVF), 2019–2023, single inherited arrhythmia clinic in Canada
- Comparison
- SCVF vs IVF vs healthy controls
- Outcome
- Circulating autoantibodies targeting cardiac ion channels (peptide microarray)
Main finding
As reported in the abstract
Anti-TREK-1 autoantibodies
SCVF
50%
7 events
- Anti-TREK-1 autoantibodies in SCVF
- P = 0.049
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| VF recurrence in SCVF probands · median 4.3 months (IQR 0.3-20.7) | SCVF 79% |
Patch clamp function of anti-TREK-1 autoantibodies
- Channel-activating, antagonized by quinidine in HEK293 cells and hiPSC-derived cardiomyocytes
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation. Circulation. Published 24 September 2024. doi:10.1161/circulationaha.124.070284
Summarised from the published abstract; every number is checked against it